SURVYR

PRGO

Perrigo Company plc
$16.02
+$0.20 (1.26%)Oct 27 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-57%-39%-21%-3%+15%Oct 2025Oct 2026Apr 202652w high $22.0252w low $9.23
PRGOSPY
Wall St. Highest PT $20.00 (+24.8%) Wall St. Avg PT $16.50 (+3.0%)
$9$12$15$18$21POC $11Hi $20Avg $16
Underwater Drawdown %Max DD -56.9%Current -21.8%
0.0%-56.9%
Relative Strength vs SPY-35.4% vs SPYUnderperforming
+73%0%-73%
1W
−$0.15 (0.93%)
1M
+$0.60 (3.89%)
3M
+$5.93 (58.74%)
6M
+$5.03 (45.74%)
YTD
+$3.02 (23.21%)
1Y
−$4.47 (21.83%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
4 analysts · mean score 2.60
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$16.02
Average target$16.50
+$0.48 (+3.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$14.00
Median$16.50
High$20.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-02-27 · Canaccord Genuity reiterated Buy on PRGO
Reiterated
2025-12-15 · JP Morgan reiterated Neutral on PRGO
Reiterated
2025-11-06 · Canaccord Genuity reiterated Buy on PRGO
Downgrade
2025-11-06 · JP Morgan downgraded PRGO from Overweight to Neutral
Reiterated
2025-10-27 · Jefferies reiterated Hold on PRGO
Reiterated
2025-08-07 · Canaccord Genuity reiterated Buy on PRGO
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$2.2B
P/E (next 12 months, estimated)6.6
52-week range$9.23 – $22.02
Revenue growth (latest quarter vs a year ago)-3.2%
Dividend yield7.17%
Analyst consensusHold (4)
Average analyst price target$16.50 (+3%)

What they do

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief.

Healthcare · Drug Manufacturers - Specialty & Generic
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
12th percentile in sector
D-
12-1 return: -23.8%
Percentile within its GICS sector across the S&P 1500.
Growth
6th percentile in sector
F
Revenue growth (YoY): -3.2%
Percentile within its GICS sector across the S&P 1500.
Value
91st percentile in sector
A
Forward E/P: 14.4% · EBITDA/EV: 11.4%
Percentile within its GICS sector across the S&P 1500.
Profitability
3rd percentile in sector
F
Profit margin: -41.9% · Return on equity: -48.7%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

PRGO earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Before the open
EPS consensus$0.53 range $0.47–$0.58
Revenue consensus$999.1M 4 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026$0.50est $0.36+40.9%Above estimates
May 6, 2026$0.43est $0.31+40.2%Above estimates
Feb 26, 2026$0.77est $0.78−1.3%Below estimates
Nov 5, 2025$0.80est $0.77+3.9%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 12:15:31 ET
24-1125-0225-0525-0825-1126-0226-0526-080.000.93
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.0B-3.2%
2026-03-31$969.2M–
2025-12-31$1.1B–
2025-09-30$1.0B–
2025-06-30$1.1B–

Recent dividends

2026-08-28: $0.290 · 2026-05-29: $0.290 · 2026-03-02: $0.290 · 2025-08-29: $0.290 · 2025-05-30: $0.290 · 2025-03-07: $0.290 · 2024-11-29: $0.276 · 2024-08-30: $0.276

News & catalysts

More news
Perrigo to Release Third Quarter 2026 Financial Results on November 4, 2026
PR Newswire · Oct 21
Rating changes
Reiterated
2026-02-27 · Canaccord Genuity reiterated Buy on PRGO
Reiterated
2025-12-15 · JP Morgan reiterated Neutral on PRGO
Reiterated
2025-11-06 · Canaccord Genuity reiterated Buy on PRGO
Downgrade
2025-11-06 · JP Morgan downgraded PRGO from Overweight to Neutral
Reiterated
2025-10-27 · Jefferies reiterated Hold on PRGO
Reiterated
2025-08-07 · Canaccord Genuity reiterated Buy on PRGO

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 12:15:31 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026